[March 20, 2013]

Epzicom Performance in HIV/AIDS Treatment Discussed in In-Demand GlobalData Report Published at MarketPublishers.com

With the emergence of antiretroviral treatment (ART), previously incurable HIV/AIDS has become a manageable chronic condition for most infected individuals. In the not-so-distant past, simplified dosing regimens through the advent of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have increased clinical efficiency thresholds as well as enabled patient compliance.

Epzicom has been marketed by ViiV Healthcare since its approval in 2004 by the U.S. Food and Drug Administration for use by humans living with HIV. The medicine falls within a category of nucleoside reverse transcriptase inhibitors (NRTIs); it prevents HIV from altering the genetic material of healthy CD4 cells, which is turn prevents the cells from producing new virus and decreases the viral load. Epzicom is indicated in combination with at least one other HIV drug, typically a�protease inhibitor (PI)�or a�non-nucleoside reverse transcriptase inhibitor (NNRTI).

In-demand research report "Epzicom (HIV) - Forecast and Market Analysis to 2022" drawn up by GlobalData is an essential source of detailed information andinsightful analysis on the role played by Epzicom in treating HIV/AIDS.

Report Scope:

• overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an assessment of the competitive landscape;
• detailed information on Epzicom including product description, safety and efficacy profiles as well as a SWOT analysis;
• sales forecast for Epzicom for the top nine countries from 2012 to 2022;
• sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China.

Report Details:

Title: Epzicom (HIV) - Forecast and Market Analysis to 2022

Published: January, 2013

Pages: 39

Price: US$ 6,995.00

http://marketpublishers.com/report/life_sciences/pharmaceuticals/epzicom-hiv-forecast-n-market-analysis-to-2022.html

More Comprehensive Market Research Reports by GlobalData Include:

• Isentress (HIV) - Forecast and Market Analysis to 2022
• Kaletra (HIV) - Forecast and Market Analysis to 2022
• Norvir (HIV) - Forecast and Market Analysis to 2022
• Prezista (HIV) - Forecast and Market Analysis to 2022
• Reyataz (HIV) - Forecast and Market Analysis to 2022

More in-demand market research reports by GlobalData can be found at http://marketpublishers.com/members/global_data/info.html

[ InfoTech Spotlight's Homepage ]